Cementless Oxford Partial Knee System
Biomet Manufacturing Corp · Decision date Oct 6, 2026
What did the FDA decide?
The FDA record lists P010014/S119 as a 30-day notice for the Cementless Oxford Partial Knee System, with decision OK30 dated 2026-10-06 and applicant Biomet Manufacturing Corp. The stated change is introduction of an additional Solvent Wash Step to the final cleaning of the femoral and tibial components at the Shannon, Ireland facility; the supplement reason is a process change covering manufacturer, sterilizer, packager or supplier.
The identifier places S119 as a supplement within PMA P010014, not a new approval of the whole knee system, and the notice concerns cleaning-process scope rather than a clinical claim. The record gives no solvent identity, wash parameters, validation data or residue limits. The reported purpose is a manufacturing change; the entry alone does not prove safety or clinical effectiveness of the resulting components.
FDA approval order statement
introduction of an additional Solvent Wash Step to the final cleaning of the femoral and tibial components of the Oxford Cementless Partial Knee System at the Shannon, Ireland facility
- Regulatory pathway
- PMA supplement
- Supplement type
- 30-Day Notice
- Clinical specialty
- Orthopedic
- Decision date
- Oct 6, 2026
- FDA change category
- Process Change - Manufacturer/Sterilizer/Packager/Supplier
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- P010014/S119
- Regulatory pathway
- PMA supplement
- Applicant
- Biomet Manufacturing Corp
- Product code
- NRA
- Decision code
- OK30
- Decision date
- Oct 6, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Prosthesis, knee, femorotibial, unicompartmental, semi-constrained, metal/polymer, mobile bearing.
- Applicant
- Biomet Manufacturing Corp
- Product code
- NRA
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P010014. Subsequent supplements may change the device or its indications.
FDA decision timeline
P010014 · Original PMA
OXFORD(TM) MENISCAL UNICOMPARTMENTAL KNEE SYSTEM
P010014/S119 received
Application receipt date recorded by FDA.
P010014/S118 · Related supplement
Oxford Partial Knee Anatomic Vivacit-E Meniscal Bearings
P010014/S119 · FDA decision
30-Day Notice
P010014/S120 · Related supplement
Oxford Partial Knee System
Timeline entries are records held by MedtechLedger for P010014. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P010014
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Biomet Manufacturing Corp | PMA approval | Apr 21, 2004 | FDA | |
| Biomet Manufacturing Corp | PMA supplement | Sep 1, 2026 | FDA | |
Oxford Partial Knee SystemP010014/S120 | Biomet Manufacturing Corp | PMA supplement | Oct 26, 2026 | FDA |
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Biomet Manufacturing Corp
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 56 E. Bell Dr.,, P.O. Box 587, Warsaw, IN, 46581
Sources and methodology
- Original FDA record: P010014/S119
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records

